Related Experiment Video

Updated: Jun 25, 2026

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Clozapine-induced cardiotoxicity: a clinical update

Jamie J Layland1, Danny Liew, David L Prior

  • 1St Vincent's Hospital, Melbourne, VIC, Australia. jamie_layland@health.qld.gov.au

The Medical Journal of Australia
|February 18, 2009
PubMed

Insights

Clozapine can cause serious heart problems like myocarditis in schizophrenia patients. Early detection using echocardiography and B-type natriuretic peptide levels is crucial for managing clozapine-induced cardiotoxicity.

Area of Science:

  • Cardiology
  • Psychiatry
  • Pharmacology

Background:

  • Clozapine is essential for treatment-resistant schizophrenia.
  • Cardiac complications, including myocarditis, cardiomyopathy, and pericarditis, are known risks.
  • Diagnosing clozapine-induced myocarditis is challenging due to non-specific symptoms.

Purpose of the Study:

  • To review diagnostic tools for clozapine-induced cardiotoxicity.
  • To highlight the importance of early detection and management.
  • To discuss the role of echocardiography and B-type natriuretic peptide.

Main Methods:

  • Review of literature on clozapine cardiotoxicity.
  • Discussion of diagnostic modalities.
  • Emphasis on clinical suspicion and supportive care.

Main Results:

  • Myocarditis is a significant, though often subtle, cardiac risk of clozapine.
  • Transthoracic echocardiography is a practical diagnostic aid.
  • B-type natriuretic peptide may aid in evaluation and future screening.

Conclusions:

  • Prompt recognition and management of clozapine cardiotoxicity are vital.
  • Cessation of clozapine and supportive care are the primary treatments.
  • Further research into screening asymptomatic patients is warranted.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...